News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Daniel Sumarriva: Prevalence and molecular correlates of acquired EGFR resistance mutations in NSCLC
Daniel Sumarriva/LinkedIn
Apr 24, 2025, 08:57

Daniel Sumarriva: Prevalence and molecular correlates of acquired EGFR resistance mutations in NSCLC

Daniel Sumarriva, Senior Director of Molecular Science Liaisons at Caris Life Sciences, shared a post on LinkedIn about a paper he co-authored with colleagues published in Expert Review of Anticancer Therapy:

“After profiling over 45,000 NSCLC tumors, the documentation of EGFR resistant data, including the prevalence of resistance mutations (718, 721, 797, etc.) in lung cancer, is essential to raise awareness about the significance of repeating molecular profiling post-TKI failure to gain a more precise understanding of resistance mechanisms.
Grateful for the opportunity to work on this publication with Dr. Luis E Raez – Memorial Cancer Institute. A team effort with our Caris Life Sciences Precision Oncology Alliance (POA). Congrats to all the authors: Yasmine Baca, Jennifer Ribeiro, Stephen Liu, Jorge Nieva, Hirva Mamdani, Gilberto de lima Lopes, Hossein Borghaei, Hina Khan, Misako Nagasaka, Antoinette Wozniak and institutions.”

“Prevalence and molecular correlates of acquired EGFR resistance mutations in non-small cell lung cancer (NSCLC)”

Authors: Luis Raez, Yasmine Baca, Jennifer Ribeiro, Jorge Nieva, Hirva Mamdani, Gilberto Lopes, Hossein Borghaei, Mark Socinski, Antoinette Wozniak, Ari Vanderwalde, Carlos Carracedo Uribe, Daniel Sumarriva, Hina Khan, Stephen Liu and Misako Nagasaka.

Daniel Sumarriva: Prevalence and molecular correlates of acquired EGFR resistance mutations in NSCLC

More posts featuring Daniel Sumarriva.

Antoinette Wozniak Ari Vanderwalde cancer Caris Life Sciences Carlos Carracedo Uribe Daniel Sumarriva EGFR Gilberto Lopes Hina Khan Hirva Mamdani Hossein Borghaei Jennifer Ribeiro Jorge Nieva Luis Raez Lung cancer Mark Socinski Misako Nagasaka non small cell lung cancer NSCLC OncoDaily Oncology POA Precision Oncology Alliance Stephen Liu Yasmine Baca
Special Coverage
Blog
Apr 24, 2025, 11:19
Bichoy Gabra: An illustration of the genes and pathways associated with targeted drugs for NSCLC
Blog
Apr 24, 2025, 11:06
New dosing options for PD-1 inhibitor in first- and second-line esophageal squamous cell carcinoma - BeOne Medicines
Blog
Apr 24, 2025, 10:57
Patients’ voices must guide the way we shape healthcare policies and systems - Digestive Cancers Europe
Blog
Apr 24, 2025, 10:50
Susanna Fletcher Greer: MMBD - a place where "stories of scientific discovery and medical progress come alive"
Blog
Apr 24, 2025, 10:48
Looking forward to hearing from the incredible physicians and scientists from MSK at the AACR annual meeting 2025
Blog
Apr 24, 2025, 10:39
Tanja Obradovic: Improved PFS versus current SOC of taxane, trastuzumab and pertuzumab
Blog
Apr 24, 2025, 10:30
Mirna Mohanraj: Engaging with communities of people within and outside the Mount Sinai Health System walls
Blog
Apr 24, 2025, 10:19
Taha M. Mehemed: Improving Health Outcomes for Children with Cancer in Libya
Science
Apr 24, 2025, 10:12
Myeloma Paper of the Day, April 24th, suggested by Robert Orlowski
Blog
Apr 24, 2025, 10:10
Joe Daccache: The largest multimodal foundation models in Oncology
Blog
Apr 24, 2025, 10:02
The Schwarz Family and Friends Cancer Research Fund to support IU brain cancer research - IU Simon Comprehensive Cancer Center
Oncolibrary
Apr 24, 2025, 09:55
Ocular Side Effects Of CAR-T Cell Therapy